Europe will have to wait for Ascendis Pharma's weekly growth hormone
The Danish biotech firm will not be launching its weekly drug until mid-2023 in Europe, despite already having marketing authorization in the region, Ascendis reveals in its second-quarter report.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Ascendis Pharma, which is based in Copenhagen, Denmark, is busy getting growth hormone Skytrofa established on the US market, which means Europe will have to take a back seat.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis Pharma reports promising phase III data
For subscribers
Novo Nordisk ready to go toe to toe with Ascendis
For subscribers
